{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:21:35Z","timestamp":1769127695919,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["F32HL159912-01"],"award-info":[{"award-number":["F32HL159912-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["TOPORE21B0"],"award-info":[{"award-number":["TOPORE21B0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["F32HL159912-01"],"award-info":[{"award-number":["F32HL159912-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["TOPORE21B0"],"award-info":[{"award-number":["TOPORE21B0"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Since the approval of elexacaftor\/tezacaftor\/ivacaftor (ETI), data suggest that there have been changes in the management of pulmonary exacerbations (PEx) of cystic fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Given the subjective nature of PEx diagnosis and management, we sought to characterize provider PEx management practices in people with cystic fibrosis (pwCF) prescribed highly effective modulator therapy (HEMT) and to identify practice changes that may impact clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted semistructured qualitative interviews among clinicians in the United States from late 2021 to 2022 to investigate changes in the management of PEx in pwCF prescribed ETI. Inductive coding of transcripts was used in a thematic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We conducted 19 qualitative interviews with providers at 15 cystic fibrosis centers. Thematic analysis identified five themes regarding the presentation, diagnosis, and management of PEx in pwCF prescribed ETI. 1) PEx have changed in the era of HEMT to become a more subtle pathology that may result in providers questioning PEx diagnosis. 2) Providers feel less anxious about clinical outcomes after PEx. 3) Providers are expanding their assessment of PEx in the era of HEMT to identify more subtle PEx phenotypes. 4) pwCF are driving their care during PEx more than in the pre-HEMT era, with interviewees reporting that some \u201cpatients don\u2019t really contact us [with mild PEx symptoms].\u2026 We hear about it in retrospect.\u201d Interviewees expressed concern that this may result in more severe PEx. 5) Provider management is less aggressive in the post-HEMT era, reflecting reduced PEx severity. Participants emphasized that their approach to PEx in general is unchanged and that \u201c[providers] treat depending on severity \u2026 and the background of the patient.\u201d Interviewees reported they increasingly recommend maintenance therapies for PEx treatment before prescribing antibiotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Participants report that PEx in pwCF prescribed ETI appear milder, resulting in less anxiety about outcomes and a more conservative approach to management. Providers express uncertainty regarding the diagnosis of PEx, given its evolving presentation and reduced in-person evaluation. Further research is necessary to identify sensitive markers of PEx and to assess the impact of conservative management on clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202408-831oc","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T10:32:31Z","timestamp":1741170751000},"page":"992-997","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":0,"title":["Provider Practices in Pulmonary Exacerbations of Cystic Fibrosis in the Era of Highly Effective Modulator Therapy"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0902-0422","authenticated-orcid":false,"given":"Alexandra","family":"Toporek","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Psoter","sequence":"additional","affiliation":[{"name":"Division of General Pediatrics, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Lechtzin","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin A.","family":"Riekert","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0025-2422","authenticated-orcid":false,"given":"Natalie E.","family":"West","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2026012203122884900_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.200405-667OC","article-title":"One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis","volume":"171","author":"Ellaffi","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203122884900_bib2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/thx.2011.161117","article-title":"Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis","volume":"66","author":"de Boer","year":"2011","journal-title":"Thorax"},{"key":"2026012203122884900_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcf.2012.03.009","article-title":"Risk factors for rate of decline in FEV1 in adults with cystic fibrosis","volume":"11","author":"Konstan","year":"2012","journal-title":"J Cyst Fibros"},{"key":"2026012203122884900_bib4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"key":"2026012203122884900_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-3-030-42382-7_9","volume-title":"Cystic fibrosis: a multi-organ system approach","author":"Montemayor","year":"2020"},{"key":"2026012203122884900_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.123.1.20","article-title":"Factors influencing outcomes in cystic fibrosis: a center-based analysis","volume":"123","author":"Johnson","year":"2003","journal-title":"Chest"},{"key":"2026012203122884900_bib7","doi-asserted-by":"crossref","first-page":"e20162642","DOI":"10.1542\/peds.2016-2642","article-title":"Characterization of inpatient cystic fibrosis pulmonary exacerbations","volume":"139","author":"Cogen","year":"2017","journal-title":"Pediatrics"},{"key":"2026012203122884900_bib8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2017.04.003","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations","volume":"16","author":"West","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026012203122884900_bib9","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203122884900_bib10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203122884900_bib11","doi-asserted-by":"crossref","first-page":"190112","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur Respir Rev"},{"key":"2026012203122884900_bib12","article-title":"Defining the new CF in the era of highly effective modulators","author":"Taylor-Cousar","year":"2020"},{"key":"2026012203122884900_bib13","author":"Cystic Fibrosis Foundation Patient Registry","year":"2022"},{"key":"2026012203122884900_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7812\/TPP\/21.089","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor on hospitalizations and intravenous antibiotic use","volume":"26","author":"Walter","year":"2022","journal-title":"Perm J"},{"key":"2026012203122884900_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcf.2017.06.002","article-title":"Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor","volume":"17","author":"Flume","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2026012203122884900_bib16","first-page":"3","article-title":"CFTR modulator therapies\u2014effect on life expectancy in people with cystic fibrosis","volume":"42","author":"Balfour-Lynn","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"2026012203122884900_bib17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1467-9566.2010.01272.x","article-title":"The role of topic, interviewee and question in predicting rich interview data in the field of health research","volume":"32","author":"Ogden","year":"2010","journal-title":"Sociol Health Illn"},{"key":"2026012203122884900_bib18","doi-asserted-by":"crossref","first-page":"160940691773384","DOI":"10.1177\/1609406917733847","article-title":"Thematic analysis: striving to meet the trustworthiness criteria","volume":"16","author":"Nowell","year":"2017","journal-title":"Int J Qual Methods"},{"key":"2026012203122884900_bib19","doi-asserted-by":"crossref","first-page":"e0232076","DOI":"10.1371\/journal.pone.0232076","article-title":"A simple method to assess and report thematic saturation in qualitative research","volume":"15","author":"Guest","year":"2020","journal-title":"PLoS One"},{"key":"2026012203122884900_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/104973239500500201","article-title":"The significance of saturation","volume":"5","author":"Morse","year":"1995","journal-title":"Qual Health Res"},{"key":"2026012203122884900_bib21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jcf.2021.02.012","article-title":"The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis","volume":"20","author":"VanDevanter","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026012203122884900_bib22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1752-699X.2011.00246.x","article-title":"Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience","volume":"6","author":"Briggs","year":"2012","journal-title":"Clin Respir J"},{"key":"2026012203122884900_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/thx.2003.005876","article-title":"Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis","volume":"59","author":"Thornton","year":"2004","journal-title":"Thorax"},{"key":"2026012203122884900_bib24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/ppul.20878","article-title":"Effectiveness of home treatment for patients with cystic fibrosis: the intravenous administration of antibiotics to treat respiratory infections","volume":"43","author":"Termoz","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"2026012203122884900_bib25","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1513\/AnnalsATS.202303-245OC","article-title":"A pilot randomized clinical trial of pediatric cystic fibrosis pulmonary exacerbations treatment strategies","volume":"20","author":"Sanders","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203122884900_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcf.2022.07.002","article-title":"Telehealth and CFTR modulators: accelerating innovative models of cystic fibrosis care","volume":"22","author":"Prickett","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026012203122884900_bib27","doi-asserted-by":"crossref","first-page":"784692","DOI":"10.3389\/fped.2021.784692","article-title":"Patient and provider experience with cystic fibrosis telemedicine clinic","volume":"9","author":"Hendra","year":"2021","journal-title":"Front Pediatr"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/7\/992\/66007444\/annalsats_22_7_992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/7\/992\/66007444\/annalsats_22_7_992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:13:17Z","timestamp":1769069597000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/7\/992\/8381906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202408-831oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2024-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}